OCU-410

Ocugen (NASDAQ: OCGN), a Pennsylvania-based biotechnology company, reported 12-month topline data from its Phase II ArMaDa trial showing that OCU410, a one-time subretinal gene therapy, reduced geographic atrophy lesion growth by 31% versus control — a result that, if confirmed in a larger trial, could position the therapy as a mechanistically distinct alternative to the repeat-injection complement inhibitors currently on the market. Trial specifics The ArMaDa trial is a Phase I/II, randomized, controlled, open-label study in 51 patients aged 50 and older with geographic atrophy secondary to dry age-related macular degeneration. Patients were randomized 1:1:1 to receive a single subretinal injection of OCU410 at a medium dose (1×10¹⁰ vector genomes), a high dose (3×10¹⁰ vector genomes), or no treatment. The primary endpoint was change in lesion size at 12 months measured by fundus autofluorescence. At the medium dose — which Ocugen has selected for Phase III — lesion growth was reduced by 31% compared to control (p<0.05). Ellipsoid zone loss, an exploratory biomarker of photoreceptor integrity, was 27% slower in the treated group. The company reported that 55% of treated patients achieved at least a 30% reduction in lesion growth relative to control. A subgroup of patients with baseline lesions between 5 mm² and 17.5 mm² showed a 33% reduction in the medium-dose arm, with the high-dose arm producing a similar effect. No serious adverse events related to OCU410 were reported. The company noted no cases of endophthalmitis, retinal detachment, vasculitis, choroidal neovascularization, or ischemic optic neuropathy across either dose arm, consistent with the safety profile observed in Phase I. Development context OCU410 is an AAV5-based gene therapy that delivers RORA (retinoid-related orphan receptor alpha), a nuclear receptor involved in regulating oxidative stress response, complement activity, inflammation, and lipid metabolism in the retina. Unlike the two approved therapies for geographic atrophy — pegcetacoplan (Syfovre, Apellis Pharmaceuticals) and avacincaptad pegol (Izervay, Astellas/Iveric Bio) — which target individual complement proteins C3 and C5 respectively, OCU410 is designed to act across multiple pathways implicated in retinal degeneration. Its single-administration dosing model also contrasts with the chronic injection schedules required by the complement inhibitors, which call for intravitreal injections every one to two months. Ocugen cited the 31% reduction at 12 months as approximately double the treatment effect reported for approved therapies, referencing 15% and 22% reductions at 12 and 24 months respectively. These figures appear to correspond to published data from the pivotal trials of pegcetacoplan and avacincaptad pegol. Cross-trial comparisons are limited by differences in study design, patient populations, dosing regimens, and sample size. The ArMaDa trial enrolled 51 patients versus the several hundred in the Phase III programs for both complement inhibitors, and the open-label, untreated-control design differs from the sham-controlled, masked methodology used in those registrational studies. The absence of a sham procedure in ArMaDa introduces the possibility of assessment bias, though fundus autofluorescence is a relatively objective imaging measure. The treatment landscape for geographic atrophy has shifted since the US FDA approved pegcetacoplan in February 2023 and avacincaptad pegol in August 2023. Both drugs slow lesion growth but do not halt or reverse it, and both carry a signal for increased rates of choroidal neovascularization. Real-world adoption has been tempered by the injection burden and patient dropout rates associated with chronic dosing. Neither therapy is approved outside the United States. A one-time gene therapy that could deliver durable efficacy without repeated injections would address a practical limitation of the current standard of care, though the durability of OCU410’s effect beyond 12 months has not yet been demonstrated. Ocugen stated it plans to initiate a Phase III registrational trial in the third quarter of 2026, with an adaptive design enrolling up to 300 subjects and powered at over 95%. The company framed this program within a broader goal of three Biologics License Application filings over three years. OCU410 has received Advanced Therapy Medicinal Product classification from the European Medicines Agency, which may facilitate regulatory engagement in the EU. The data will need to be evaluated in the context of the full dataset when presented at a scientific meeting, and several questions remain open. Whether the treatment effect increases, stabilizes, or diminishes beyond 12 months will be central to the value proposition of a one-time therapy competing against drugs with established two-year efficacy data. The functional significance of the ellipsoid zone preservation signal — and whether it translates into measurable visual acuity benefit — will also be scrutinized, as the Phase II trial did not report visual function outcomes. The 51-patient sample, while adequate for a Phase II signal-finding study, provides limited statistical power for subgroup analyses, and the reported subgroup results should be interpreted with caution. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website